PZ Cormay SA

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: PLCMRAY00029
PLN
0.42
-0.1 (-18.85%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

Poor Management Efficiency with a low ROE of 0%

  • The company has reported losses. Due to this company has reported negative ROE
2

Poor long term growth as Net Sales has grown by an annual rate of 8.77% and Operating profit at 11.60% over the last 5 years

 
3

Risky -

4

Consistent Underperformance against the benchmark over the last 3 years

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

PLN 35 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.03

stock-summary
Return on Equity

-4.69%

stock-summary
Price to Book

0.74

Revenue and Profits:
Net Sales:
25 Million
(Quarterly Results - Sep 2025)
Net Profit:
0 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-18.85%
0%
-18.85%
6 Months
0.96%
0%
0.96%
1 Year
-27.24%
0%
-27.24%
2 Years
-43.58%
0%
-43.58%
3 Years
-53.98%
0%
-53.98%
4 Years
-65.69%
0%
-65.69%
5 Years
-62.32%
0%
-62.32%

PZ Cormay SA for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
8.77%
EBIT Growth (5y)
11.60%
EBIT to Interest (avg)
-2.83
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
1.64
Tax Ratio
0.76%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0

Valuation key factors

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.74
EV to EBIT
-15.99
EV to EBITDA
10.21
EV to Capital Employed
0.75
EV to Sales
0.39
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-4.67%
ROE (Latest)
-7.58%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
Bearish
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is 12.83% vs -0.88% in Jun 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is 84.00% vs -516.67% in Jun 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Jun'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "25.50",
          "val2": "22.60",
          "chgp": "12.83%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1.70",
          "val2": "0.10",
          "chgp": "1,600.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.20",
          "val2": "0.30",
          "chgp": "-33.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.10",
          "val2": "-0.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-0.40",
          "val2": "-2.50",
          "chgp": "84.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "9.80%",
          "val2": "-60.50%",
          "chgp": "7.03%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 11.44% vs -3.75% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -15.22% vs 34.29% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "91.60",
          "val2": "82.20",
          "chgp": "11.44%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "0.60",
          "val2": "-0.60",
          "chgp": "200.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.90",
          "val2": "0.90",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1.10",
          "val2": "3.00",
          "chgp": "-136.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-5.30",
          "val2": "-4.60",
          "chgp": "-15.22%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-54.10%",
          "val2": "-69.20%",
          "chgp": "1.51%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQstock-summary

Sep'25
Jun'25
Change(%)
Net Sales
25.50
22.60
12.83%
Operating Profit (PBDIT) excl Other Income
1.70
0.10
1,600.00%
Interest
0.20
0.30
-33.33%
Exceptional Items
-0.10
-0.10
Consolidate Net Profit
-0.40
-2.50
84.00%
Operating Profit Margin (Excl OI)
9.80%
-60.50%
7.03%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Sep 2025 is 12.83% vs -0.88% in Jun 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Sep 2025 is 84.00% vs -516.67% in Jun 2025

Annual Results Snapshot (Consolidated) - Dec'24stock-summary

Dec'24
Dec'23
Change(%)
Net Sales
91.60
82.20
11.44%
Operating Profit (PBDIT) excl Other Income
0.60
-0.60
200.00%
Interest
0.90
0.90
Exceptional Items
-1.10
3.00
-136.67%
Consolidate Net Profit
-5.30
-4.60
-15.22%
Operating Profit Margin (Excl OI)
-54.10%
-69.20%
1.51%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 11.44% vs -3.75% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -15.22% vs 34.29% in Dec 2023

stock-summaryCompany CV
About PZ Cormay SA stock-summary
stock-summary
PZ Cormay SA
Pharmaceuticals & Biotechnology
PZ Cormay SA is a Polish-based producer and wholesaler of diagnostic reagents and a distributor of the laboratory equipment. The Company is engaged in the design, manufacture and distribution of a range of products for clinical chemistry, hematology, electrophoresis, parasitology, cytology, coagulation and specific protein recognition. It offers drugs, biochemical rapid tests and devices such as vacuettes and tubes. PZ Cormay SA provides also biochemical analyzers: ACCENT-300, ACCENT-200, PRESTIGE 24i and LIVIA; hematological analyzers: MYTHIC 18, among others, and urinalysis apparatus: IChem 100. On September 1, 2014, Orphee SA acquired 100% stake in TT Management Sp z o o to enable execution of the restructuring plan of Cormay group which aims at transferring production and distribution activity of Cormay group to Orphee SA.
Company Coordinates stock-summary
Company Details
Ul. Wiosenna 22 , LOMIANKI None : 05-092
stock-summary
Tel: 48 22 751791048 692 823744
stock-summary
Registrar Details